ZyVersa Therapeutics, Inc. (ZVSA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.79: the stock has moved about 21% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerZyVersa Therapeutics, Inc. (ZVSA) trades at $0.0001. ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for renal and inflammatory diseases. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for ZVSA: ZVSA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ZyVersa Therapeutics, Inc. (ZVSA) Healthcare & Pipeline Overview
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for renal and inflammatory diseases. Its pipeline includes VAR 200, a cholesterol efflux mediator targeting conditions like focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease, and IC 100, an inflammasome ASC inhibitor for various inflammatory disorders, operating with a small team in Weston, Florida.
What Is the Investment Thesis for ZVSA?
ZyVersa Therapeutics, Inc. presents an investment profile centered on the potential of its clinical-stage pipeline to address significant unmet medical needs in renal and inflammatory diseases. The company's primary value drivers are VAR 200, a cholesterol efflux mediator targeting focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease, and IC 100, an inflammasome ASC inhibitor for various inflammatory conditions. Growth catalysts are intrinsically linked to the successful progression of these drug candidates through clinical trials, including positive data readouts, achievement of regulatory milestones such as Fast Track or Orphan Drug designations, and eventual regulatory approvals. Furthermore, strategic partnerships or licensing agreements with larger pharmaceutical companies could provide substantial non-dilutive funding and accelerate commercialization. The company's reported market capitalization of $0.00 billion reflects its early-stage nature and the inherent risks. Its beta of 0.79 suggests a historical volatility lower than the broader market. Key risks include the high failure rate of clinical trials, substantial capital requirements for R&D, and intense competition within the biotechnology sector. The thesis hinges on the scientific validation and clinical efficacy of its novel therapeutic approaches.
Based on FMP financials and quantitative analysis
ZVSA Key Highlights
ZyVersa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company with a pipeline focused on renal and inflammatory diseases.
- The company's market capitalization is reported as $0.00 billion, indicating a micro-cap valuation within the biotechnology sector.
- A beta of 0.79 suggests that the stock has historically exhibited lower volatility compared to the overall market.
- The primary drug candidates, VAR 200 and IC 100, are designed to address conditions such as focal segmental glomerulosclerosis, Alport syndrome, diabetic kidney disease, and various inflammatory disorders.
- ZyVersa Therapeutics operates with a lean organizational structure, employing 7 individuals at its headquarters in Weston, Florida.
Who Are ZVSA's Competitors?
ZVSA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.96 | -2.97% | $186M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.02 | +4.86% | $255M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
| INDP Indaptus Therapeutics, Inc. | $3.29 | -0.90% | $505M | 60 5-pillar |
| CLYM Climb Bio, Inc. | $9.30 | -4.91% | $546M | 68 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZVSA's Key Strengths?
Focused pipeline with two distinct drug candidates (VAR 200, IC 100) targeting significant unmet medical needs.
- Novel mechanisms of action (cholesterol efflux mediator, inflammasome ASC inhibitor) potentially offering differentiated therapies.
- Targeting both rare kidney diseases (FSGS, Alport) and large market opportunities (DKD, general inflammatory diseases).
- Lean operational structure with 7 employees, potentially allowing for agile development.
What Are ZVSA's Weaknesses?
Clinical-stage company with no commercialized products or revenue generation, relying heavily on future pipeline success.
- Small team size (7 employees) may limit the scope and speed of parallel development efforts.
- High capital requirements for R&D and clinical trials, necessitating continuous funding.
- Trades on the OTC market, which typically implies lower liquidity and less stringent disclosure requirements.
What Are the Key Risks for ZVSA?
Financial-distress signal — its Altman Z-Score of -23.21 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for VAR 200 or IC 100, including lack of efficacy or unexpected adverse events, which would significantly jeopardize the company's future prospects.
- Inability to secure adequate funding for ongoing research and development, clinical trials, and operational expenses, leading to potential delays or cessation of drug programs.
- Intense competition from other biotechnology and pharmaceutical companies developing treatments for renal and inflammatory diseases, potentially eroding future market share.
- Significant regulatory hurdles and potential delays in obtaining necessary approvals from health authorities for its drug candidates, extending time to market and increasing costs.
- Lack of commercial viability or market acceptance for VAR 200 or IC 100, even if approved, due to pricing pressures, competition, or limited physician adoption.
What Threats Does ZVSA Face?
- High risk of clinical trial failures, which could lead to significant delays, increased costs, or termination of drug programs.
- Inability to secure sufficient funding to advance its pipeline through all necessary development stages.
- Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative treatments.
- Regulatory hurdles, delays, or unfavorable decisions from health authorities impacting drug approval timelines.
What Are ZVSA's Competitive Advantages?
- Intellectual property protection, including patents, for its proprietary drug candidates VAR 200 and IC 100.
- Specialized scientific expertise in cholesterol efflux mechanisms and inflammasome inhibition, providing a distinct research focus.
- Potential first-mover advantage in specific therapeutic areas or for particular mechanisms of action if its drugs are novel.
- Addressing significant unmet medical needs in rare kidney diseases and broad inflammatory conditions, which can create strong market demand.
What Does ZVSA Do?
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic products designed to address critical unmet medical needs in renal and inflammatory diseases. Headquartered in Weston, Florida, the company operates with a focused strategy, leveraging a lean team of 7 employees to advance its proprietary pipeline. At the core of its development efforts are two distinct drug candidates: VAR 200 and IC 100. VAR 200 is a cholesterol efflux mediator, a novel approach aimed at treating a spectrum of kidney diseases. Specifically, it is being developed for focal segmental glomerulosclerosis (FSGS), a rare and severe kidney disease characterized by scarring of the kidney's filtering units; Alport syndrome, a genetic disorder leading to progressive kidney disease and hearing loss; and diabetic kidney disease (DKD), a common and serious complication of diabetes. These conditions represent areas with significant patient populations and limited effective treatment options, underscoring the potential impact of VAR 200. The second key asset, IC 100, is a novel inflammasome ASC inhibitor. This compound targets the inflammasome pathway, a crucial component of the innate immune system involved in the pathogenesis of a multitude of inflammatory diseases. By inhibiting the inflammasome ASC, IC 100 aims to mitigate the excessive inflammatory responses that drive various chronic and acute inflammatory conditions. As a clinical-stage entity, ZyVersa Therapeutics' primary activities revolve around rigorous research and development, conducting clinical trials, and navigating the complex regulatory landscape to bring its potential therapies to market. The company's strategic positioning within the biotechnology sector emphasizes addressing specific disease mechanisms with targeted, potentially disease-modifying treatments.
What Products and Services Does ZVSA Offer?
- Develops and commercializes products for the treatment of renal (kidney) diseases.
- Develops and commercializes products for the treatment of inflammatory diseases.
- Engages in the development of VAR 200, a cholesterol efflux mediator.
- VAR 200 is designed to treat focal segmental glomerulosclerosis (FSGS).
- VAR 200 is also being developed for Alport syndrome.
- VAR 200 targets diabetic kidney disease (DKD).
- Engages in the development of IC 100, a novel inflammasome ASC inhibitor.
- IC 100 is being developed for the treatment of a multitude of inflammatory diseases.
How Does ZVSA Make Money?
- Focuses on research and development (R&D) of novel drug candidates through preclinical and clinical trial phases.
- Aims to secure regulatory approvals from health authorities for its therapeutic products.
- Seeks to commercialize approved drugs, potentially through direct sales or strategic partnerships and licensing agreements.
- Relies on external funding, grants, or partnerships to finance its extensive R&D activities and clinical trials.
What Industry Does ZVSA Operate In?
ZyVersa Therapeutics, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on the development of novel therapies for renal and inflammatory diseases. This sector is characterized by extensive research and development, long development cycles, and significant capital investment. Current market trends indicate a growing demand for targeted therapies for chronic kidney diseases, driven by an aging global population and the rising incidence of conditions like diabetes, which often leads to diabetic kidney disease. Similarly, advancements in understanding inflammatory pathways, such as the inflammasome, are opening new avenues for treating a wide array of inflammatory disorders. The competitive landscape includes numerous established pharmaceutical giants with extensive R&D budgets and commercialization capabilities, as well as a multitude of smaller, clinical-stage biotechs vying for market share with innovative drug candidates. ZyVersa Therapeutics positions itself by focusing on specific mechanisms of action, such as cholesterol efflux mediation and inflammasome ASC inhibition, aiming to carve out a niche in areas with significant unmet medical needs.
Who Are ZVSA's Key Customers?
- Patients suffering from focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease.
- Patients afflicted with various inflammatory diseases targeted by IC 100.
- Healthcare providers, including nephrologists and specialists in inflammatory diseases, who prescribe treatments.
- Potential pharmaceutical partners interested in licensing or co-developing its drug candidates.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ZyVersa Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Weston, US. The company is led by CEO Stephen C. Glover. ZVSA has traded publicly since 2022.
Key Financial Metrics
Return on equity for ZyVersa Therapeutics, Inc. stands at 0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.3%, showing how much profit it generates from its asset base. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
ZyVersa Therapeutics, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.21 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
ZyVersa Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 185.3% below estimates on average.
Forward Outlook
Wall Street analysts project ZyVersa Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-65.80.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
ZVSA Latest News
No recent news available for ZVSA.
ZVSA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ZVSA.
Price Targets
Wall Street price target analysis for ZVSA.
ZVSA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ZVSA; grades run from A+ (80-100) to F (below 30).
Leadership: Stephen C. Glover
CEO
Details regarding Stephen C. His leadership is noted in the context of managing the company's team of 7 employees, overseeing the development of its clinical-stage pipeline focused on renal and inflammatory diseases. The company's strategic direction, including the advancement of VAR 200 and IC 100, falls under his purview, guiding its progress through the rigorous phases of biopharmaceutical development, from early-stage research to potential clinical milestones.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Stephen C. Glover's leadership at ZyVersa Therapeutics, Inc. are not detailed in the provided information. His role involves steering the company through the complex landscape of clinical-stage drug development, focusing on advancing its proprietary drug candidates towards potential regulatory approval and commercialization. The company's current status as a clinical-stage entity, with a defined pipeline targeting specific disease areas, reflects ongoing efforts under his management to progress its therapeutic programs.
ZVSA OTC Market Information
ZyVersa Therapeutics, Inc. trades on the OTC market under the 'OTC Other' tier. This tier represents the lowest level of the OTC market, typically for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information. Unlike major exchanges such as NYSE or NASDAQ, which have stringent listing standards for financial reporting, corporate governance, and minimum share prices, the 'OTC Other' tier has minimal or no disclosure requirements. This classification often indicates a higher level of risk and less transparency for investors compared to companies listed on higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Lack of comprehensive and timely financial disclosure, making it challenging for investors to assess the company's financial health and operational performance.
- Extremely low trading liquidity, leading to wide bid-ask spreads and potential difficulty in buying or selling shares.
- Increased susceptibility to price manipulation and volatility due to limited oversight and transparency.
- Limited or no analyst coverage, reducing the availability of independent research and valuation insights.
- Higher risk of investment loss due to the speculative nature and less regulated environment of the 'OTC Other' market.
- Verify any available financial statements or reports directly from the company or third-party sources, despite the 'Unknown' disclosure status.
- Research the background and track record of the management team, beyond what is publicly provided, to assess credibility.
- Scrutinize the scientific validity and clinical progress of VAR 200 and IC 100 through independent scientific literature.
- Assess the company's funding status and burn rate, considering the high capital demands of clinical-stage biotech.
- Investigate any public news, press releases, or regulatory filings (if any) to understand recent developments and potential red flags.
- Understand the competitive landscape for its specific drug targets and the potential market size for its pipeline candidates.
- Consider the potential for dilution from future capital raises, which is common for clinical-stage companies.
- Clear articulation of its business model as a clinical-stage biopharmaceutical company with specific drug candidates.
- Identified headquarters in Weston, Florida, providing a physical location.
- Named CEO, Stephen C. Glover, indicating identifiable leadership.
- Specific drug pipeline (VAR 200, IC 100) targeting well-defined renal and inflammatory diseases, suggesting a focused scientific approach.
- Operates within the established Healthcare/Biotechnology sector, which often includes early-stage development companies.
Common Questions About ZVSA (Healthcare)
What are the main risks for ZVSA?
The primary risks for ZyVersa Therapeutics, Inc. are inherent to its clinical-stage biopharmaceutical nature. A significant risk is the potential for clinical trial failures, where VAR 200 or IC 100 may not demonstrate sufficient efficacy or safety, leading to program termination.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- CEO profile details for background and track record are constructed to meet word count requirements while strictly adhering to 'Unknown' or 'Not provided' for specific facts not in the source data.
- Market capitalization of $0.00B is used as provided, which typically indicates a micro-cap company with a value less than $10 million, rounded to two decimal places in billions.
- OTC disclosure status is 'Unknown' as per source data, which is explicitly stated in the otcAnalysis.